Acousticabio, Inc.
Cambridge, MA
- UEI
- PQD4VEHVHWD6
- CAGE
- 9GAD2
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 277 Broadway #1st, Cambridge, MA 02139, USA
- Website
- acoustica.bio
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $295,116 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| High-dose and sustained delivery of HIV-1 broadly neutralizing antibodies via subcutaneous injection of… | National Institute of Allergy and Infectious Diseases (NIH) | $295,116 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Emmune Inc. | Cambridge, MA | — |
| Integral Molecular Inc. | Philadelphia, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Acrobiosystems Inc. | Newark, DE | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Antagen Biosciences Inc. | Canton, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Partillion Bioscience Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Acousticabio, Inc., a for-profit biotechnology company based in Cambridge, Massachusetts, operates as a federal research grant recipient developing hydrogel-based drug-delivery formulations for therapeutic monoclonal antibodies, working exclusively as a prime recipient under NIH SBIR Phase I and Phase II programs with no subcontract footprint.
Acousticabio's federal work focuses on engineered subcutaneous delivery of high-concentration monoclonal antibodies through alginate-based microgel and microparticle formulations. The company received a $295,116 SBIR Phase I contract award from the National Institute of Allergy and Infectious Diseases (NIAID) on August 1, 2024, for development of hydrogel-based microparticle formations enabling high-dose and sustained delivery of HIV-1 broadly neutralizing antibodies via subcutaneous injection, with ultimate completion scheduled for September 30, 2025. Acousticabio also holds two federal grants from the National Center for Advancing Translational Sciences (NCATS): a $931,463 SBIR Phase II award dated August 1, 2026 (CFDA 93.350), running through May 31, 2028, to develop alginate-based microgels for ultra-high concentration antibody formulations enabling self-administered subcutaneous delivery in 1–2 milliliter volumes versus hundreds of milliliters for intravenous administration; and a prior SBIR Phase I grant dated August 1, 2023, with ultimate completion on July 31, 2024, addressing similar subcutaneous delivery challenges for therapeutic monoclonal antibodies via hydrogel microparticles.
Customer concentration is entirely within HHS NIH, split between NIAID (one award, $295 thousand combined potential value) and NCATS (two awards). The combined potential value of all three awards totals $295 thousand, though obligated dollars across all awards reached approximately $2 million. One award (the 2024 SBIR Phase I) completes within the next twenty-four months and faces recompete. Acousticabio operates exclusively under SBIR set-aside vehicles with no prime contract vehicle seats and no subcontractor relationships; all work is performed in Cambridge, Massachusetts, under primary NAICS 541712 (Research and Development in the Physical, Engineering, and Life Sciences).
Quick answers
Is Acousticabio, Inc. registered in SAM.gov?
Yes. Acousticabio, Inc.'s SAM.gov registration is active through September 23, 2027.
What is Acousticabio, Inc.'s CAGE code?
Acousticabio, Inc.'s CAGE code is 9GAD2, and its Unique Entity ID (UEI) is PQD4VEHVHWD6.
How much has Acousticabio, Inc. received in federal contracts?
Federal contracts obligated $295,116 to Acousticabio, Inc. in fiscal years 2023 through 2027.
What is Acousticabio, Inc.'s most recent federal award?
Acousticabio, Inc.'s most recent federal grant award is Enabling subcutaneous delivery of antibodies via microgel-based, ultra-high concentration formulations (R44TR006344), from National Center for Advancing Translational Sciences (NIH), on August 1, 2026.
On GovTribe
See Acousticabio, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors